Clinical TrialsFDA agreed to the use of a single primary endpoint of change from baseline in the 3 cardinal symptoms score, which simplifies the study requirements.
Market PotentialIf the pursuit of LYR-210 FDA approval focuses on the CRSsNP patient population, it targets roughly 70% of CRS patients, which represents a significant portion of the market.
Therapeutic AppealThe LYR-210 sinonasal drug implant is designed to deliver 6-months of continuous anti-inflammatory corticosteroid therapy based on a single administration, which is appealing from a therapeutic standpoint.